男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語(yǔ)Fran?ais
China
Home / China / Latest

Sinopharm's COVID-19 vaccine remained active against S.Africa variant: study

Updated: 2021-02-05 17:09
Share
Share - WeChat
A sign of Sinopharm is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the COVID-19 outbreak, in Beijing, Sept 5, 2020. [Photo/Agencies]

Two COVID-19 vaccines from Chinese companies including Sinopharm triggered immunity against a highly transmissible coronavirus variant first found in South Africa, but their effect appeared weaker, a small-sample lab study released on Tuesday showed.

Variants of the virus have stirred concern that they might weaken effects of vaccines and treatments developed prior to their emergence.

Twelve serum samples each taken from recipients of two vaccines developed by a subsidiary of China National Pharmaceutical Group (Sinopharm) and a unit of Chongqing Zhifei Biological Products retained neutralising activity against the South African variant, their researchers said in a paper.

The paper was written by researchers from Sinopharm-affiliated Beijing Institute of Biological Products, the Institute of Microbiology of Chinese Academy of Sciences, which is co-developing a candidate with Zhifei unit, and two other Chinese agencies.

However, the samples' activity against the variant was weaker than against the original virus and another variant currently spreading globally, according to the paper published on website BioRxiv ahead its peer-review.

The activity reduction "should be taken into account for its impact for the clinical efficacy of these vaccines," they said.

The Sinopharm vaccine is approved in China for general public use and is also used in several other countries including the United Arab Emirates. The Zhifei shot is in late-stage clinical trials in China and overseas.

Preliminary clinical trial data on vaccines from Novavax Inc and Johnson & Johnson also showed they were significantly less effective at preventing COVID-19 in trial participants in South Africa, where the potent new variant is widespread.

Reuters

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 偃师市| 开远市| 渑池县| 岢岚县| 依安县| 澳门| 保山市| 花莲市| 延津县| 丽江市| 宜春市| 龙岩市| 湘潭县| 阿瓦提县| 上饶市| 无棣县| 乌拉特中旗| 屯昌县| 察雅县| 亚东县| 江达县| 隆安县| 定陶县| 东宁县| 肇州县| 汤阴县| 辽阳县| 晋城| 镇平县| 通化市| 密云县| 嘉义市| 灌阳县| 乡城县| 武冈市| 大同市| 岐山县| 鄂尔多斯市| 齐齐哈尔市| 讷河市| 浪卡子县|